Hospital Clinical Chemistry and Immunodiagnostics Market - Global Markets & Advanced Technologies

Hospital clinical chemistry refers to the area of clinical pathology related to the analysis of body fluids such as blood, urine, etc. and immunodiagnostics is a diagnostic method based on antigen-antibody reaction. There have been remarkable advances in the field of clinical chemistry and immunodiagnostics, resulting into potential diagnostic platform and technologies such as molecular diagnostics, spectrophotometry, electrophoresis, measurement of enzyme activities, and separation of molecules. Clinical chemistry and immunodiagnostics play a critical role to aid the clinicians in the prevention, diagnosis and treatment of diseases. Diseases generally diagnosed with the help of clinical chemistry include viral and bacterial infection, diabetes, thyroid, kidney failure, heart problems, cystic fibrosis in new born babies and screening for illegal drug use.

Based on types of tests, the hospital clinical chemistry and immunodiagnostics market can be segmented as follows:

• Clinical chemistry
• Routine chemistry: It is generally used for the analysis of blood for various tests such as kidney function tests
• Special chemistry: This branch of clinical chemistry uses advanced methods such as electrophoresis
• Drug monitoring: It measures the therapeutic drug medication level in order to determine the right dosage
• Endocrinology: This clinical chemistry test involves the study and diagnosis of endocrine disorders
• Toxicology: It involves the study of drugs of abuse
• Urinalysis: Urinalysis refers to the analysis of urine sample to diagnose a wide array of diseases
• Immunodiagnostics
• Enzyme-Linked ImmunoSorbent Assay or ELISA: ELISA is a commonly used laboratory test that uses a solid-phase enzyme immunoassay (EIA) to detect antibody in the blood sample
• Radioimmunoassay: It is an in vitro assay technique used for the measurement of hormone levels in the blood. One of the examples of radioimmunoassay is the RAST test (radioallergosorbent test) which is used to detect the presence of causative allergen for a specific allergy.

Based on geography, the hospital clinical chemistry and immunodiagnostics market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). North America holds a leading position in the market followed by Europe. The prime factors which are responsible for the growth of hospital clinical chemistry and immunodiagnostics market in these regions are increasing prevalence of various diseases among the population, and the growing need for technologically advanced diagnostic tests. Moreover, major breakthrough developments in clinical chemistry and immunodiagnostics have resulted in reduction of immunoassay duration and complexity, thereby spurring the growth of the market. Asia Pacific is one of the lucrative markets for the growth of hospital clinical chemistry and immunodiagnostics market due to various emerging economies. Factors which would contribute towards the growth of the market in Asia Pacific are growing need of the population for rapid and cost-effective immunoassay procedures and novel diagnostic platforms. Cost-savings can be achieved with the aid of clinical chemistry and immunodiagnostics due to highly centralized operations and automated data analysis.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6925

Various advances in diagnostic technologies, automation and huge competition in the hospital clinical chemistry and immunodiagnostics market is paving way for a number of opportunities. A number of top companies operating in the market are Abbott, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Siemens AG, Danaher Corporation, Bio-Rad Laboratories, Inc., Alere and others.

Single-Dose Therapy Market Segment Forecast up to 2024

Single-dose therapy can be defined as single drug, or a combination of two or more active pharmaceutical ingredients (API) to be administered in a single dosage form. The drugs combined in the single dosage form contributes to the synergistic effects claimed by each of the drug. The number of doses of the single dose therapy can be increased or decreased, but the therapy does not involving altering of API proportion in the dosage form. These are administered in the form of a vial, capsules, tablets or patch.

Single-dose therapy market can be segmented based on disease indication, application, distribution channel, and geography. Based on disease indication, the market can be segmented into cancer, HIV/AIDS, sexually transmitted diseases, neurological disorders, psychological disorders, and microbial infections, among others. On the basis of application, single-dose therapy market can be segmented into human health and animal health. Hospitals, ambulatory centers, clinics, and pharmacies form the major distribution channels for the market. Based on geography, the market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

Increasing demand due to the synergistic effects provided by the combined fixed dose API’s administered as a single dose is the major driver for the single-dose therapy market. Further, the simpler treatment regime, convenience of administration, and the cost saving offered by single-dose therapy are also expected to drive the market growth. Additional benefits include the combined pharmacokinetics of the component drugs employed in the single dose, and enhanced medication compliance. However, the dosage of the APIs in the single-dose cannot be modified according to the patient requirements, which might negatively impact the growth of the market. In addition, the adverse side effects caused by the component drugs, the allergic reactions from any of the component drugs in the single dose therapy cannot be avoided, which might have an impact on the patient health, and a negative effect on the market growth. Also, the growing over-the-counter sale of various non-approved fixed dose combinations administered as single dose, would adversely affect the market.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13718

The increasing incidence of sexually transmitted diseases (STDs), and various forms of cancer in all the geographies would drive the demand for single-dose therapies and contribute to the growth of the market. Geographically, North America is the largest market for single-dose therapy, followed by Europe. The growing geriatric population, and increased focus on research and development of effective single dose therapies has been driving the use of single-dose therapies. In addition, the growing FDA approvals of new single-dose therapies would contribute to the growth of the market. For instance, in November 2015, the U.S. FDA approved Genvoya, a single dosage form of various combination drugs for the treatment of HIV-1 infection. Asia Pacific is expected to record significant growth during the forecast period, attributed to the growing economy in the emerging markets of Asia Pacific, growing awareness among people and the increasing geriatric population.

The leading players in the single-dose therapy market include Allergan plc, AstraZeneca plc, Bayer AG, BioCryst Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Merck & Co., Novartis AG, Pfizer, Inc., and Sanofi S.A., among other significant global market players.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Polymerase Chain Reaction (PCR) Market - An insight on the important factors and trends influencing the market

PCR techniques have paved the way for innovation in life sciences research and molecular diagnostics through its most potential features such as absolute detection and quantification of genetic materials such as DNA and RNA. Researchers are able to quantify and analyze rare alleles and point mutations using advanced PCR systems such as digital PCR. Currently, the market players are engaged in developing PCR systems with enhanced capabilities such as broad menu of tests, higher sensitivity and specificity. Other major advances associated with the PCR include shorter turnaround times (PCR cycling time), higher productivity and automated workflow; thereby ensuring efficient detection and amplification of genetic materials with accurate results. The market is witnessing significant advances in the design of PCR platforms shifting from conventional standard PCR to real time and digital PCR systems to efficiently detect pathogenic microbes such as mycobacterium tuberculosis bacteria and influenza viruses. For instance, introduction of QX200 Droplet Digital PCR System by Bio-Rad provides a broad menu of molecular diagnostic tests and enhanced workflow to enable overall cost reduction and eliminate the need for multiple systems. The global PCR market is valued at USD 6,065 million in 2013 and is expected to reach USD 9,621.0 million with the CAGR of 6.6% during the forecast period of 2014 to 2020.

Although, the use of PCR has been mostly confined to research institutions, pharmaceutical and biotechnology industries, currently, the market has seen an increasing preference of PCR in the commercial diagnostic laboratories and hospitals due to precise diagnoses of life-threatening diseases such as cancer and Ebola. Multi-chain diagnostic laboratories are currently focusing on expanding their operations in less developed areas by acquiring standalone laboratories with minimal infrastructure. Therefore, a strong demand for compact and portable PCR with high reliability and sensitivity is created. All these features along with high affordability are expected to provide impressive growth opportunities for PCR market.

The PCR market is broadly classified on the basis of product segments, end-users and application areas. Among the product segments, reagents and consumables remain the most widely used segment with the largest share in the net sales across various companies, considering the global sales of USD 4,072.2 million in 2013. Among various end-users of PCR, academics and research organization was accounted for the largest market share of overall market in 2013, followed by clinical diagnostic labs and hospitals segment. However, clinical diagnostics segment is likely to grow at an impressive pace during the forecast period of 2014 to 2020. Among the PCR applications area, the life sciences segment is the largest application area covering more than 48% of the total PCR market followed by clinical diagnostics segment with 33% of the market share. The majority market share by the life sciences segment corresponded to its wider acceptance in the cancer research, which is also amongst the oldest segments of PCR application.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=830

Geographically, North America accounted for the largest share of global PCR market in 2013 followed by Europe. These two regions are expected to retain their position throughout the forecast period 2014 to 2020. This is majorly attributed to the presence of technologically sophisticated diagnostic laboratories along with wider acceptance of novel assay technologies. The North American region was among the first to approve and implement the PCR based assays for diagnosis of infectious diseases such as HIV. The Asia Pacific region on the other hand is expected to represent the highest growth rate during the forecast period. This can be attributed to the growing investment in research and development in the region by the Government and private investors. China for example, is at present the world’s second largest investor in research and development according to the World Bank data.

The overall PCR market is consolidated and characterized by the presence of few established players accounting for more than 50% of the total market share. Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Agilent Technologies and Sigma-Aldrich Corporation Beckman Coulter, Bio-Rad, Becton Dickinson and QIAGEN are some of the key players operating in this market.

Medical Plastics Market Witnesses Rising Demand and Investment from R&D Activities

Transparency Market Research holds a large compilation of research reports on the healthcare industry and the medical devices industry. One of the latest titles under the latter is the “Medical Plastics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 – 2018,” which aims to assess the various strengths, weaknesses, opportunities, and restrictions that the market will experience over the given forecast period.

The greatest factor responsible for the growth of the global medical plastics market is the increasing demand for disposable medical devices. A large number of healthcare organizations are insisting on disposable medical devices as they help maintain a better standard of hygiene and prevent the reuse of devices such as syringes and needles. Another driver of the global medical plastics market is the increasing need for better quality plastics that can increase the shelf life of medical devices. Other factors promoting the growth of this market are the increasing trade of medical devices due to relaxing international trade laws and an increase in the overall expenditure on healthcare.

There are also the improvements in the materials themselves that are again pushing the global medical plastics market forward. These include the reduction in weight of the plastics without compromising on durability and the safe use of non-metallic i.e., plastic medical devices around magnetic fields created by medical equipment such as the MRI.

One of the restrictions on the global medical plastics market is the care that needs to be taken in disposing the plastic medical devices. Bodies such as the Healthcare Plastics Recycling Council, or the HPRC are active in this space. The HPRC can provide assistance to medical organizations in managing the safe disposal of medical devices. This is a highly advantageous step for medical bodies towards adhering to the increasingly stringent regulations imposed by governments pertaining to the control of ecological damage caused by unmonitored disposal.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1115

The use of plastics in the healthcare sector spans a wide array of fields, including packaging, in most types of modern medical devices, and especially the disposable medical devices.

From a regional perspective, the U.S. has consistently held the largest share in the global medical plastics market in the recent past. The nation’s dominant position is attributed to its highly advanced healthcare infrastructure, the presence of key global players, and the high medical expenditure coupled with greater awareness of the use of quality medical devices.

The key players in the global medical plastics market include Alcan Packaging, Tekni Plex Corporation, ExxonMobil Corporation, Saint Gobain Performance Plastics, Cyro Industries, Bayer, Du Pont, The DOW Chemical Company, Baxter International, Becton and Dickinson, and BASF SE.

Medical devices outsourcing emerged as cost-effective solution in various disciplines of medicine

The global medical devices outsourcing market is driven by rising demand for quality healthcare services, ongoing developments in the field of medical technology, and parallel operational requirements to cut costs for long term sustainability.The global market, which is seeing a rising trend of services and product outsourcing by leading global players to small and specialized service providers in emerging markets, is broadly categorized into product outsourcing and services outsourcing markets.

The medical devices services market is highly diversified and market leaders are expanding their portfolio to tap the high potential. The global medical devices market can be segmented based on factors such as – Application: Class I medical devices, Class II medical devices, and Class III medical devices, and Services: Product design and development services, Regulatory consulting services, Product testing services, Product implementation services, Product upgrade services, and Product maintenance services. Geographically, the market is segmented into Asia Pacific,Europe, North America, andRest of the World (RoW).

Competition amongst medical device manufacturers and the urge to increase profit margins is driving the demand for medical devices outsourcing. Increased product recalls have also boosted demand for services such as testing services and validation services. Among all the geographic regions,North America holds the largest share of medical devices outsourcing market due to the growing healthcare costs. The high penetration and coverage by medical insurance providers in the region too is further helping to boost the demand for quality healthcare services, forcing industry players to outsource services. The fast developing Asia Pacific market is continuously attracting foreign players to leverage market potential, and as a result, service providers in the region are continuously looking for higher and advanced quality certifications.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=361

Within the medical devices manufacturing industry, orthopedic devices constitute the leading share with cardiology devices quickly catching up as the fastest growing device type being outsourced for manufacturing services. The need for integration of other supportive technologies, such as telecommunications, digital imaging and diagnostics, robotics, and many more is further contributing to the market growth and guiding the entry of players from different industries into the market. By application, Class II devices are the largest market share holder due to moderate associated risks and limited regulatory requirements. However, due to high technical and manufacturing cost containment challenges, product design services form the largest market segment of all other medical device services outsourced. Also, outsourcing is helping companies to focus on other business activities and manage their product life cycles, which again is driving the market growth.

Orthodontic Equipment and Consumables Market - Latest Trends & Insights 2020

The heavily consolidated global orthodontics equipment and consumables market is dominated by Danaher Corporation, DENTSPLY International Inc., and Patterson Companies Inc. According to Transparency Market Research, these three leading players accounted for 63.5% of the orthodontic equipment and consumables market in 2013, with the next two companies collectively accounting for more than 20% of the market.

Apart from the aforementioned market leaders, A-Dec Inc., Midmark Corporation, Ultradent Products Inc., 3Shape A/S, Zimmer Holdings Inc., and Sirona Dental Systems Inc. are among the key manufacturers of orthodontic equipment and consumables.

Increasing Demand for Cosmetic Dentistry Leads to Rising Demand for Orthodontics Equipment

The prime drivers for the global orthodontic equipment and consumables market are the increasing demand for cosmetic dentistry. The high prevalence of malocclusions (incorrect bite) has led to an increase in orthodontic procedures to correct the jaw structure. The increasing demand to improve one’s appearance by altering one’s dental structure has also boosted the demand for orthodontic equipment and consumables.

The booming dental tourism in emerging Southeast Asian countries is another crucial driver for the global orthodontic equipment and consumables market. The ease of traveling to countries that offer advanced medical services at much cheaper rates than in developed countries has led to many Westerners traveling to Southeast Asian dental tourism hubs in recent years. This is likely to remain an influential driver for the global orthodontic equipment and consumables market in the coming years.

On the other hand, the key restraint on the market is the apathy among the general population about dental care. The high costs of advanced orthodontic equipment and consumables are another key constraint acting on the market.

CAD/CAM Systems Exhibiting Robust Growth, Dental Radiology to Retain Dominance

Among the various types of equipment used in orthodontic procedures, dental radiology equipment is the leading contributor to the orthodontic equipment and consumables market. However, CAD/CAM systems have exhibited a robust growth rate since the early part of the decade and have become increasingly important in orthodontics thanks to the steady incorporation of progressive technological advancements. Among orthodontic consumables, brackets have always been the dominant segment, and are likely to remain the leading contributor to the orthodontic equipment and consumables market in the coming years.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2357

Geographically, North America is the dominant market for orthodontic equipment and consumables, with a revenue of US$3.3 bn expected in 2016, and is likely to retain its lead in the coming years. Europe and Asia Pacific also remain key contributors to the global orthodontic equipment and consumables market, with the latter expected to exhibit by far the highest CAGR of all regional segments in the 2014-2020 forecast period – 10.9%.

The global orthodontic equipment and consumables market is expected to be valued at close to US$7.8 bn by 2016 and further rise to US$11 bn by 2020. The information presented in this review is based on a Transparency Market Research report titled ‘Orthodontic Equipment and Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.’

Postmenopausal Hormone Therapy Market Dynamics and Opportunities Report by Transparency Market Research

Post menopause is the period occurred after menopause followed by various syndromes like vaginal dryness, hot flashes, etc. During this period level of estrogen and progestin falls significantly leading to even serious complications like osteoporosis. The worldwide market for Postmenopausal Hormone Therapy is gaining moment substantially. This rising demand for Postmenopausal Hormone Therapy is due to increasing level of awareness about menopausal symptoms and its treatment. Another factor is growing population of post-menopausal women. Postmenopausal Hormone Therapy includes replenishment of body level of estrogen and progestin hormones in women through external intake of hormones. Thus, it help in treating the menopausal symptoms. It decreases the symptoms like vaginal dryness, hot flashes, disturbed sleep, night sweats and etc. The Postmenopausal Hormone Therapy helps in prevention of osteoporosis and hot flashes caused due to depletion of estrogen and progestin level in body. The Postmenopausal Hormone Therapy comprises of natural as well as synthetic estrogens. In order to enhance the menopausal treatment, it is also given in combination with progesterone.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13568

The treatment for post – menopausal syndrome is generally treated with sequential or continuous schedules through various doses of estrogen, progestin or combination of both. Despite of existing controversy and confusion about the safety profile of the postmenopausal hormone therapy, the market for the postmenopausal hormone therapy has recorded positive inclining growth due to growing demand. The development of postmenopausal hormone therapy with respect to driving demand leads to introduction of highly safe treatment options to patients which include development of novel drug delivery system like vaginal estrogen drugs and transdermal estrogen patches. Low dose postmenopausal hormone therapy are used in order to address the backdrop caused due to safety issues. The non-hormonal treatment has comparatively least efficacy to produce optimum results, hence the postmenopausal hormone therapy market is observed to grow significantly.

However, the major retarding factors to the market include the affordability to the therapy. The cost for postmenopausal hormone therapy approximately revolves around US$ 10,000 per annum, and thus incurring a major burden on the patients’ pocket. Thus the population from developing and under – developed countries faces a challenge of affordability for the postmenopausal hormone therapy. The post treatment risk of cervical cancer and coronary disease are another restraining factors for the market. Approved recognition of the products related to postmenopausal hormone therapy in compounding pharmacies particularly from developed countries is another deterring factor. However the opportunity for the market is the introduction of the product targeting the cardiovascular disease prevention.

The Postmenopausal Hormone Therapy market can be segmented by product, by therapy, by dosage form, by route of administration, by end-user and by geography. In the terms of product, the postmenopausal hormone therapy is classified into patches, tablets, creams, suppositories, and injections. The tablet formulation comprises the largest market share of the total postmenopausal hormone therapy market. However, due to growing concern of safety and long-term therapy the market for the patches are growing at much faster compound annual growth rate. Based on the therapy, the market is segmented into individual progestin, estrogen and combination therapies. The majority of market is occupied by estrogen therapy across the world.

Based on the route of administration, the postmenopausal hormone therapy market is classified into oral, topical and subcutaneous implants. Due to high safety, oral administration has been the preferred choice of option for the patient. However, introduction of novel drug delivery system has driven the market for topical and subcutaneous products as well. In the terms of end-user, the target population are the women suffering from menopause. However, the treatment is influenced by the physician/ gynecologist, the target end-users are hospitals and specialty clinics.

Geographically, North America occupies the largest market share followed by other developed region like Europe. The United States accounts for a major share of the global market. The high awareness level and high purchasing power in this region led the market of postmenopausal hormone therapy for expansion significantly. However, the same factor of affordability has restrained the markets in developing regions. Despite of this, Asia Pacific has shown striking increase in its growth rate for the postmenopausal hormone therapy market. Rising population, increase in disposable income, and increase in awareness level are some key factors driving the Asia Pacific Market. Due to this factors, the Asian market is observing high number of new entrants compared to those in developed regions.

The Major players reported in the market include Abbott Laboratories, AbbVie, Inc., Bayer Pharma AG, Hisamitsu Pharmaceutical Co., Inc., Novartis AG, Novo Nordisk A/S, Orion Pharma AB, Pfizer, Inc., Meda pharmaceuticals, Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc., etc

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Global CTCs Prognostic Technologies Market to Reach US$0.43 Bn by 2020 due to Rising Prevalence of Cancer

Clinical Information Systems (CIS) is a computer aided system that manages, stores and rechecks all medical information in hospitals such as health history of patients, prescriptions, doctor\'s notes and any other special comment whereas all information is electronically kept together. By capturing clinical data CIS makes the decision making process and clinical care delivery more efficient and effective and also helps to replace the paper work. Apart from this it helps by computerization of repetitive tasks, high accuracy, automated recording of medical equipments observations and results. Functions of clinical information systems are not limited to a single area such as diagnosis data management of laboratory data management but are more widespread and comprising practically all aspects of clinical information.

According to study conducted by The Johns Hopkins Medicine Institute, 40 percent of physicians exceeded their expected number of patients seen in a typical day. Increasing prevalence and incidences of various critical diseases have increased the load on hospitals to diagnose and treat more number of patients with high level of efficiency and accuracy. All these factors have lead to increase in demand for the sophisticated management systems to handle patients’ clinical related data. Looking at the technologically advancement in this market and increasing patient load on every hospital in both developed and developing countries, it can be estimated that there may be considerable growth of the market in coming years. At the same time growing number of state of art healthcare facility centers across the world, may drastically increase demand for the CIS. On the other side, rapidly changing technology, high cost involved in installation and maintenance of CIS and requirement of professional training to handle CIS hindering the growth of the market. Clinical information systems are widely spread in western world healthcare providers, however, their function are mainly restricted to financial and administrative functions, rather than having a direct support for patients or assisting physicians and other professionals in their daily work.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2572

Market for clinical information systems can be segmented geographically and according to its usage in various types of services and products offered such as cloud based and web based. Geographically CIS market is segmented in four regions namely North America, Europe, Asia-Pacific and Rest of the World. North America and Europe are the leading geographic regions followed by Asia-Pacific and Rest of the World respectively. On the other side, according to services, CIS market can be segmented in cloud based and web based market, out of which though web based is major but growth for the cloud based systems are comparatively on higher side. Parallel to this, the market for CIS can be divided in three categories namely hardware, software and services. The market for hardware and software is relatively higher than that of services required for maintaining CIS. There are some companies which are catering exclusively in all these three segments in the market. There are special guidelines issued by U.S. FDA regarding the use of information systems in healthcare facilities majorly focused on easy to use, data safety and training of the personnel.

Some of the market players in Clinical Information Systems market include Clinicmaster, Quintiles, Accenture, Allegro CTMS, iMDsoft and thermo scientific, Surgical Information Systems LLC.

Clinical Information Systems Market Dynamics and Opportunities Report by Transparency Market Research

Clinical Information Systems (CIS) is a computer aided system that manages, stores and rechecks all medical information in hospitals such as health history of patients, prescriptions, doctor\'s notes and any other special comment whereas all information is electronically kept together. By capturing clinical data CIS makes the decision making process and clinical care delivery more efficient and effective and also helps to replace the paper work. Apart from this it helps by computerization of repetitive tasks, high accuracy, automated recording of medical equipments observations and results. Functions of clinical information systems are not limited to a single area such as diagnosis data management of laboratory data management but are more widespread and comprising practically all aspects of clinical information.

According to study conducted by The Johns Hopkins Medicine Institute, 40 percent of physicians exceeded their expected number of patients seen in a typical day. Increasing prevalence and incidences of various critical diseases have increased the load on hospitals to diagnose and treat more number of patients with high level of efficiency and accuracy. All these factors have lead to increase in demand for the sophisticated management systems to handle patients’ clinical related data. Looking at the technologically advancement in this market and increasing patient load on every hospital in both developed and developing countries, it can be estimated that there may be considerable growth of the market in coming years. At the same time growing number of state of art healthcare facility centers across the world, may drastically increase demand for the CIS. On the other side, rapidly changing technology, high cost involved in installation and maintenance of CIS and requirement of professional training to handle CIS hindering the growth of the market. Clinical information systems are widely spread in western world healthcare providers, however, their function are mainly restricted to financial and administrative functions, rather than having a direct support for patients or assisting physicians and other professionals in their daily work.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2572

Market for clinical information systems can be segmented geographically and according to its usage in various types of services and products offered such as cloud based and web based. Geographically CIS market is segmented in four regions namely North America, Europe, Asia-Pacific and Rest of the World. North America and Europe are the leading geographic regions followed by Asia-Pacific and Rest of the World respectively. On the other side, according to services, CIS market can be segmented in cloud based and web based market, out of which though web based is major but growth for the cloud based systems are comparatively on higher side. Parallel to this, the market for CIS can be divided in three categories namely hardware, software and services. The market for hardware and software is relatively higher than that of services required for maintaining CIS. There are some companies which are catering exclusively in all these three segments in the market. There are special guidelines issued by U.S. FDA regarding the use of information systems in healthcare facilities majorly focused on easy to use, data safety and training of the personnel.

Some of the market players in Clinical Information Systems market include Clinicmaster, Quintiles, Accenture, Allegro CTMS, iMDsoft and thermo scientific, Surgical Information Systems LLC.

Mice Model Market - Innovation towards industrial scale-up

In the last couple of decades, mouse modelling has emerged as a premier mammalian model system for conducting effective genetic research. Mice models have long remained the basis of fundamental and applied research in life science, and are continuing to exhibit robust growth. Due to the close psychological and genetic similarities between mice and humans, scientists hailing from diverse biomedical fields have gravitated to mice models. Furthermore, the ease with which the genomes of mice can be manipulated and analyzed has also given a boost to the global mice model market.

In its latest report, Transparency Market Research has pegged the overall value of the global mice model at US$1 bn in 2014. The market is projected to reach US$1.7 bn by the end of 2023. If the figures hold true, the global mice model market will exhibit a 6.4% CAGR between 2015 and 2023. Although worms, yeasts, and flies are considered excellent models for scrutinizing the cell cycle and development process, mice have proven to be a far better tool for studying the nervous, skeletal, cardiovascular, endocrine, immune, and other complex physiological systems that mammals share.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2085

Genetic Similarities of Mice with Other Mammals Boost Market for Mice Model

Like humans and several other mammals, mice often develop diseases that negatively affecttheir immune systems such as cancer, diabetes, oestoporasis, hypertension, glaucoma, and others. Furthermore, certain diseases that affect humans but do not naturally occur in mice, such as Alzheimer’s and cystic fibrosis, can be induced in mice by manipulating their genome to study the effect of novel therapeutics in the treatment of such ailments. The demand for mice model, therefore, increases with the rising funding in research and development to find possible cures for chronic ailments.

Mice present low cost of maintenance and have the ability to multiply rapidly, reproducing as often as nine weeks. This further adds to their appeal as models for biomedical research.

Development of New Therapeutics with Mice Models Propels Mice Model Market

Development of mice models for studying the effects of potential therapeutics in the treatment of certain specific diseases and debilitating health conditions has accelerated tremendously in the last couple of years. The development has been so rapid that mice models have become indispensable in the evaluation of both pipeline and established treatment modalities, particularly in cases of cardiovascular diseases, cancer, neurological disorders, and metabolic anomalies.

Application of mice models in drug discovery enables the development of novel therapeutics strategies, target identification and validation, disease treatment, drug screening, and toxicity and safety screening.

Ethical Issues and Stringent Regulations Hinder Global Mice Model Market

The latest advances in genetic engineering that assist in evaluating a drug’s mechanism of action will boost the market for drug discovery. This in turn is likely to fuel demand from the mice model market. However, on the flip side, stringent regulatory frameworks precisely controlling the use of animals for research in laboratories, rising concerns pertaining to animal cruelty, and other ethical concerns related to the use of animals will have an adverse impact on the overall mice model market.

Estrogen Replacement Therapy (ERT) Market Set to Expand by 2024

The estrogen replacement therapy (ERT) is witnessing significant rise in demand and hence growth of the market globally. This rising demand for estrogen replacement therapy is mainly attributed to increasing awareness about menopausal symptoms and its treatment opportunities. Another key factor responsible for the growth of this market is growing population of the post-menopausal women requiring ERT worldwide.

Due to change in hormonal levels in the body, women suffer from various debilitating symptoms. ERT is one of the hormone replacement therapies that includes replenishment of estrogen hormone levels in women through administration of external estrogen and/or progesterone hormones. Estrogen replacement therapy helps in treating women suffering from menopausal symptoms. It decreases the symptoms like vaginal dryness, hot flashes, disturbed sleep, night sweats, etc. ERT helps in osteoporosis prevention caused due to depletion of estrogen levels in the body. ERT comprises of natural as well as synthetic estrogen hormones. In order to enhance the menopausal treatment, it is also given in combination with progesterone hormone.

The ERT market has recorded positive growth in the recent past due to growing demand for the therapy worldwide. Due to the substantial growth in demand for ERT there has been introduction of highly safe treatment options for the patients located in different geographies of the world. For instance, development of novel drug delivery systems (NDDSs) like vaginal estrogen drugs and transdermal estrogen patches. Another form of ERT such as Low dose ERT are utilized in order to address the backdrop caused due to safety concerns raised against high-dose forms. The non-hormonal treatment have proven least effective, hence the ERT market is expected to grow at a rapid pace during the forecast period.

The key restraining factor for the ERT market could be the cost of this therapy. The monthly treatment cost for ERT varies from US$ 40 to US$ 150. Therefore, the population from developing and underdeveloped countries face the challenge of affordability for the therapy. Approved recognition of the products related to ERT in compounding pharmacies particularly from developed countries is another deterring factor. The post treatment risk of cervical cancer and coronary disease can also prove to be the restraining factors for the growth of this market.

Global ERT market can be segmented based on dosage forms, routes of administration, end-users and geography. Based on dosage forms, the ERT market can be segmented into patches, tablets, gels/creams, suppositories, implants and injections. The tablet dosage form segment dominated the global ERT market in 2015. However, due to growing safety concerns and demand for effective long-term therapy, the market for injections, gels/creams and patches is expected to witness high growth during the forecast period. Based on routes of administration, the ERT market can be classified into oral, topical, subcutaneous pellets, injections, etc. Oral route of administration has remained the most preferred option for the patients’ world over. However, novel drug delivery systems such as topical and subcutaneous products have also witnessed increased demand and acceptance in the global market in the recent past.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13460

Geographically, North America especially the U.S. occupied the largest market share followed by other developed regions such as Western Europe and Japan. The U.S. have been the major market for ERT across the world due to high awareness levels and implausible purchasing power of the people in the country that further led to the expansion of ERT market in the country. However, the same factor of affordability has restrained the market in the developing regions of the world. Despite this, the emerging economies of the Asia Pacific region have displayed striking increase in the growth rates in the ERT market segment. Rising population, increasing disposable income, and improving health care awareness levels are some the key factors driving the Asia Pacific ERT market.

Some of the key players operating in the ERT market include AbbVie, Inc., Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Novartis AG, Novo Nordisk A/S, Orion Pharma AB, Pfizer, Inc., Meda pharmaceuticals, Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc. among others.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Serotonin-norepinephrine Reuptake Inhibitors Market - An insight on the important factors and trends influencing the market

Serotonin-norepinephrine Reuptake Inhibitors: Overview

Serotonin-norepinephrine reuptake inhibitors (SNRIs) or dual - uptake inhibitors represent one of the newest but important classes of antidepressants, which are commonly prescribed for anxiety disorders and depression therapeutic treatment. SNRIs were first launched in the international markets in 1993, when the U.S. FDA approved first of its kind Venlafaxine (Effexor) as an antidepressant, which would help treat numerous individuals suffering from varying anxiety disorders and/or depression.

However, SNRIs belong to that group of antidepressants, which are used as a second line treatment regimen for depression in addition to another antidepressants class called Selective Serotonin Reuptake Inhibitors (SSRIs). SNRIs work by blocking the re-absorption of two neurotransmitters in the brain, namely Norepinephrine and serotonin, thus, increasing the level of these two neurotransmitters in the nerve cells. This property of SNRIs helps elevate the mood of an individual suffering from depression or any type of anxiety disorder. No severe side effects have been observed to be associated with SNRIs usage; however, a few common side effects, such as nausea, dry mouth, excessive sweating and dizziness are generally associated with this class of antidepressants.

Serotonin-norepinephrine Reuptake Inhibitors: Key Drivers

Some of the major driving factors for the growth of this market include rising prevalence of depression and anxiety disorders globally, improved efficacy and reduced side effects of SNRIs available in the global market and rapidly increasing geriatric population. According to the WHO estimates, in 2012, more than 350 million people were found to be affected by depression worldwide. Similarly, the Anxiety and Depression Association of America (ADAA) estimated that, in 2012, around 14.8 million people in the U.S. were suffering from depression only.

Aged individuals are more prone to several depression and anxiety disorders; hence, high geriatric population in most of the developed economies and increasing age of people in developing nations will also contribute towards the growth of this market in future. Improved efficacy along with the reduction in the side effects due to SNRIs will further contribute towards the growth of this market. Some of the major drugs from this class that are available in the global market include Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima) and Venlafaxine (Effexor XR). However, the market for SNRIs may face challenges in future due to recent expirations of lot of SNRIs and a weak pipeline of drugs from this class of antidepressants, which will cause the introduction of a large number of generics in the global market.

Serotonin-norepinephrine Reuptake Inhibitors: Region-wise Insight

Geographically, North America holds the leading position in the SNRIs market followed by Europe. Key factor responsible for their dominance in this market is high prevalence of anxiety disorders and depression in these regions, especially in the U.S. According to the World Health Organization (WHO), in 2012, about 16 million adults aged 18 or above suffered from major depressive disorders in the U.S. Thus, large patient population suffering from depression and other disorders has helped the antidepressants market to grow significantly in the region. Moreover, the Centers for Disease Control and Prevention (CDC) suggested that frequent episodes of major depression were the leading cause of suicide and disability among the U.S. citizens aged between 15 years and 44 years.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13352

However, emerging economies of Asia Pacific, Middle East, LATAM and Africa regions would present huge opportunities for the growth of this market in future. Key factors responsible for the growth of this market in these regions include economic growth, increased disposable income and enhanced affordability of branded formulations in these regions. Moreover, a growing geriatric population more prone to psychiatric disorders such as depression, clinical anxiety, bipolar disorder and other psychological conditions along with the presence of a large population base in the region would consequently raise the uptake of SNRIs.

Some of the major players operating in this market are Eli Lilly and Company, Forest Laboratories, Inc. and Pfizer, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Sweeping Reforms in Healthcare Sector will Create Multibillion-dollar Opportunities for Healthcare Contract Manufacturing Outsourcing Market, reports TMR

Increasing competition in the healthcare sector has impelled major companies to concentrate on the reformation of their business strategies along with the emphasis on product manufacturing, development, design, and marketing, reports Transparency Market Research in a new study. In this regard, contract manufacturing outsourcing has become a major need for the manufacturers of pharmaceuticals and medical devices as they strive to retain their position in the market. The top three companies in the global healthcare CMO market acquire approximately 17.2% of the global revenue with Catalent Pharma Solutions Inc. leading. The company was trailed by Lonza Group and Boehringer Ingelheim GmbH.

As the global healthcare CMO market is extremely fragmented with only a few companies dominating the market, the leading companies in this segment have taken up dominant competitive strategies, strong acquisition strategies, and high product development to maintain their lead in the market. Due to the availability of similar technologies and low product differentiation, the competitive rivalry in the market is expected to rise. Moreover, leading companies are investing on research and development projects to maintain a high level of competitive rivalry.

Patent Expirations of Drugs to Adversely Impact Demand for Healthcare CMOs

In the next few years, several renowned drugs are getting off patent leading to an increase in competition among developers of drugs. Innovative drug developers are collaborating with contract manufacturing organizations to minimize the risk of heavy competition from generic drug developers due to the increasing healthcare R&D cuts by federal banks. The degeneration in the productive outcomes of R&D and the rising inquiry from regulatory bodies during the approval process of drugs has led to a substantial increase in the demand for CMOs as several leading pharmaceutical companies have started outsourcing their drug development activities.

Furthermore, the need for product innovation and post engineering support service impelled manufacturers to outsource activities such as design, validation, prototype, feasibility tests, concept, and regulatory compliance. Thus, leading companies are seeking synergy with CMOs as a result of patent expirations and decreasing R&D budget.

Emerging Economies to Provide Opportunities for the Development of CMOs in Healthcare Sector

Countries such as India, China, and Brazil are emerging as key participants in the global pharmaceutical and medical device market as they own plentiful expertise and technologies for research and development. They also back medical giants in their respective research projects regarding lifesaving drugs and advanced therapies. Thus, these countries are expected to emerge as the major destinations for the outsourcing of medical device and pharmaceuticals. Global pharmaceutical companies consider these countries to be efficient for research centers and clinical trials. Various CMOs operating outside Asia have successfully attained FDA approvals and credibility for quality standards. The sanction of Good Manufacturing Practice certificates in emerging economies, especially in Asia, has led to a substantial growth of the healthcare CMO market.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2452

Delayed Delivery of Supplies Could Dent Business Flow to CMOs

The three most important rules of the medical device and pharmaceutical industry are time to market, time to volume and time to profit. The failure of these can lead to the decline in customer satisfaction and manufacturer competitiveness. Due to the rise in the cost of research and development projects and absence of proper infrastructure and trained workforce, the pharmaceutical companies fail to diversify their product portfolio leading to a delay in supply delivery. Thus, the failure to deliver supplies on time is expected to hamper the growth of the contract manufacturing organizations market.

North America is projected to lead the global market for healthcare CMO with 32.9% followed by Asia-Pacific with a share of 31.2%. The global healthcare CMO market is anticipated to rise at a CAGR of 14.30% between 2013 and 2019 with a market worth of US$246.5 bn by the end of 2019 from a value of US$97.6 bn in 2012.

The review has been based on the findings of a TMR report titled “Healthcare CMO Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.”

Telepathology Service - Emerging technology that offers advancement of telecommunication to reach out patient in remote location

Telepathology Service Market: Overview

Telepathology refers to the electronic transmission of high quality pathological data by the means of telecommunications technology to practice pathology from a distance. It opens the door for transfer of high quality image-rich pathological data between different locations for the purposes of diagnosis, education, and research. This technology is being utilized for purposes such as expert opinion on referral cases, emergency services, diagnosis at remote location, quality assurance, conferences and meetings, and for educational training. Telepathology is an emerging technology that offers advancement of telecommunication to reach out patient in remote location and provides best diagnostic inference to distant healthcare provider.

This market research provides in-depth analysis of global telepathology service markets. It includes trends and sales in the telepathology service market. Key market players, service segments, supporting technologies, market dynamics, and competitive impact analysis are discussed in depth. The intended audience for this report includes Pathological Labs, Clinicians and Medical Practitioners, Medical Equipment Vendors, Outsourced Clinical Service Providers, Researchers and Academics, Healthcare Consultants, telecoms and tech start-ups among several other readers.

Telepathology Service Market: Growth Enablers

In the current economy, cost cutting is a cardinal driver for the advancement of any technology which offers cost effectiveness and global reach to the entire market. Accurate pathological assessment, quick diagnoses, timely treatment and delivery of high-quality healthcare are some of the prime factors that would emphasize the global market demand for telepathology.

In addition to that, the widespread presence of cancer, the increasing workload of healthcare providers, and advances in laboratory diagnostic tests drives the growth of telepathology market globally. However, the high initial setup cost and error in sampling pathological data would be catastrophic for global telepathology service market. Other factors which may restrain the telepathology services markets are rigorous regulatory requirements for telepathology systems as different issues arise in quality assurance and assessment of competence.

It is of paramount importance to have equivalence between telepathology system and pathologist`s usual method of practice in order to recognize and acknowledge differences. The telepathology system’s attributes and advantage differ from one company to the other. Every company’s system differs in their telecommunication technology, scanning software and backup. The key to establishing a presence in the telepathology service market is to have a setup with a system design for pathologists that are service provider-centric, that is based on requirements of provider and designed to meet end-user requirements.

Telepathology Service Market: Segmentation

Telepathology is primarily segmented in three domains, namely, static image-based systems, virtual slide systems, and real-time systems. The global market for telepathology is segmented based on scanning technology, application type (hospital based, home based), software and hardware configuration, clinical application and geography. An aging population in North America and Asia Pacific and rising demand for home-based treatment are expected to boost the current and future telepathology market.

23 million individuals aged 80 years or over were living in China in 2013. The USA contributed to about 12 million, followed by India and Japan, which had 10 million and 9 million, respectively. Apart from this increase expenditure in healthcare is also responsible for the shifting paradigm for future technology. It reflects the net result of the aging of the population on demand of technology that would be utilized for home based pathological diagnoses.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13427

Telepathology Service Market: Key Players

Major market players profiled in this report includes include Canada Health Infoway, University Health Network, Meyer Instruments, Inc., Telemedicine Clinic (TMC), AMD Global Telemedicine, Inc., Emerge MD, Focal Point , Nationwide Medical Licensing, Polycom, Inc, Remote Medical Technologies, USAC - Universal Service Administrative Company, Visual Share, Inc., Wolf Vision Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.